← 返回

巨噬细胞在癌症进展和靶向免疫治疗中的作用

英文原题:Role of macrophages in cancer progression and targeted immunotherapies.

查看英文原题

Role of macrophages in cancer progression and targeted immunotherapies.

PubMed 2022/12/19(内容时间) Adv Protein Chem Struct Biol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤微环境(TME)的巨大复杂性加剧了免疫逃逸、治疗耐药和治疗失败的基本原理。肿瘤细胞周围的基质细胞和免疫细胞群影响癌细胞周期,导致肿瘤进展。肿瘤相关巨噬细胞(TAMs)表现出独特的M2极化状态,构成TME的重要部分。它们在早期作为肿瘤抑制因子,在晚期通过调控各种微环境信号作为肿瘤促进因子。已知TAMs分泌的各种促肿瘤细胞因子、趋化因子和基质金属蛋白酶可调控不同的细胞周期分子,包括癌细胞中的检查点抑制剂,导致细胞周期进展并伴有缺陷的细胞成分。此外,TAMs是众所周知的免疫抑制因子,从而促进肿瘤细胞逃避免疫识别。本章将描述TAMs与肿瘤细胞之间的相互作用、TAMs通过控制细胞周期检查点或分子通路参与调控癌细胞进展,以及当前基于TAM的治疗,包括限制TAM募集、抗存活策略或转换极性。此外,本章还将强调最近开发的药物靶点和限制肿瘤进展的CAR-巨噬细胞疗法。

展开英文摘要原文

The vast complexity of the tumor microenvironment (TME) aggrandizes the underlying principles responsible for immune escape, therapy resistance, and treatment failure. The stromal and immune cell population circumjacent to the tumor cells affects the cancer cell cycle leading to tumor progression. Tumor-associated macrophages (TAMs) exhibiting a unique M2 polarization state constitute a significant portion of the TME.

They serve as tumor suppressors at early stages and tumor promoters at advanced stages by governing various microenvironmental cues. TAMs secreted various pro-tumoral cytokines, chemokines, and matrix metalloproteases are known to regulate the different cell cycle molecules including checkpoint inhibitors in cancer cells leading to cell cycle progression with faulty cellular components.

Moreover, TAMs are well-known immunosuppressors and thereby facilitating the tumor cells' evasion from immune recognition. This chapter will describe the interaction between TAMs and tumor cells, the involvement of TAMs in the regulation of cancer cell progression by controlling cell cycle checkpoints or molecular pathways, and current TAM-based therapies, including restriction of TAM recruitment, anti-survival strategies, or switching polarity.

Moreover, this chapter will also emphasize recently developed drug targets and CAR-macrophage cell therapy that restricts tumor progression.

论文信息

作者
Arora L、Kalia M、Pal D
第一作者单位
Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, Punjab, India.India
通讯作者单位
Department of Biomedical Engineering, Indian Institute of Technology Ropar, Rupnagar, Punjab, India. Electronic address: durba.pal@iitrpr.ac.in.India
期刊
Advances in protein chemistry and structural biology2023
原文标识
PubMed 37061335 · DOI 10.1016/bs.apcsb.2022.11.010